<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03897335</url>
  </required_header>
  <id_info>
    <org_study_id>Acute Kidney Injury</org_study_id>
    <nct_id>NCT03897335</nct_id>
  </id_info>
  <brief_title>Preventing Acute Kidney Injury (AKI) in Neonates</brief_title>
  <acronym>AKI</acronym>
  <official_title>The Effect of Aminophylline on Preventing Acute Kidney Injury in Neonates and Infants With Congenital Heart Disease Undergoing Open Heart Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Le Bonheur Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Le Bonheur Children's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is compare the effects of peri-operative administration of
      aminophylline (non-specific adenosine receptor antagonist) versus saline placebo in the
      preservation of renal function and the attenuation of renal injury in newborns, and young
      infants following cardiac palliative/correction surgery.

      The study rationale is Aminophylline and theophylline are competitive non-selective
      inhibitors of adenosine. Therefore, even though aminophylline infusion (iv) has no effect on
      renal blood flow rate at baseline, it can ameliorate the decrease in renal blood flow rate
      following adenosine infusion. This property can improve renal function when the main
      mechanism of insult induces vasoconstriction. Both early and late administration of
      aminophylline protects renal function after ischemia-reperfusion injury in rats.
      Aminophylline has also been reported to successfully reverse newborn renal failure, prevent
      renal failure in perinatal asphyxia, and reverse acute kidney injury secondary to calcineurin
      induced nephropathy. Both theophylline and aminophylline have been used for prophylaxis of
      renal impairment during aorto-coronary bypass surgery in adults and the results have not been
      consistent for either a positive or negative effect. There have been no trials reported on
      the effect of aminophylline or theophylline to prevent or ameliorate acute kidney injury in
      children with congenital heart defects going through cardiac surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cardiac palliative/ correction surgeries in the newborns, infants, and children involve
      significant morbidity and mortality risks. Kidney function is frequently affected from
      cardiothoracic surgery in these children. Studies identify the incidence of acute kidney
      injury (AKI) to be approximately 54% when defined by serum biomarkers (e.g. serum creatinine)
      and urine output criteria. The need for renal replacement therapy (RRT) for newborns and
      infants after cardiac surgery is reported as 2% to 17% in the literature. There are several
      reported risk factors for the development of AKI in this population. These are the complexity
      of the underlying heart disease and the surgical procedure, duration of cardiopulmonary
      by-pass, functional single ventricle heart disease, circulatory arrest and low cardiac output
      syndrome in the post-operative period. AKI can cause worsening fluid overload compromising
      ventilation and lung function, predisposition to overwhelming infections and
      cytokine-mediated inflammatory state. The presence of AKI significantly increases the
      mortality that is associated with cardiac surgery in these very young patients, reported as
      high as 79% in the literature. There have been several reports suggesting that early
      intervention with AKI using renal replacement therapy (RRT) may improve patient mortality.
      Successful prevention strategies for AKI have not been reported for this high-risk
      population.

      Newborns (term and preterm) and young infants are known to have physiological renal failure
      with their glomerular filtration rates (GFR) averaging 25-35 ml/min/1.73 m2. The newborn
      renal vasculature constriction response to intravascular depletion or poor renal perfusion is
      more vigorous than an older kidney's response. This adaptive response to preserve the
      intravascular volume and tonicity cannot be easily reversed even if the perfusion pressures
      are restored. Renal adenosine and Angiotensin II (AT-II) are important intra-renal
      vasoconstrictors resulting in worsening GFR and diuretic resistance. The young kidney is
      dependent on Angiotensin II-mediated efferent arteriole vasoconstriction to maintain GFR.
      Therefore, AT-II blockade in newborns and young infants results in oligo-anuric acute kidney
      injury and is not a safe option in this age group. However, blocking the actions of adenosine
      may restore the glomerular blood flow and recover GFR.

      Adenosine has been demonstrated to regulate renal circulation and metabolism. It is a
      breakdown product of adenosine triphosphate/adenosine diphosphate (ATP/ADP) metabolism and
      accumulates in AKI. At baseline, the barely detectable renal parenchymal adenosine levels can
      increase to 10-100 times following an ischemic insult . These are typical seven
      trans-membrane spanning domains with a coupled G-protein at the intracellular end. Adenosine
      receptors are located ubiquitously in many tissues. Adenosine acts as a vasodilator in all
      other tissues but the renal parenchyma. The interaction of AT-II with adenosine converts
      adenosine to a vasoconstrictor in renal microvasculature. Adenosine acts on the A1 receptors
      (A1 R) in the afferent arterioles, causing reduced glomerular blood flow and GFR as well as
      stimulating renin release from the kidney parenchyma. Adenosine plays an important role in
      generating the vasoconstrictive response in the renal vasculature to hypoxia and ischemia.
      Early interventions by blocking the actions of adenosine on A1 R may restore glomerular blood
      flow and recover GFR.

      Adenosine has documented effect through its other receptors that are also important in renal
      ischemia-reperfusion injury (IRI). A2a receptors (A2a R, glomerular epithelium and
      capillaries cortex, medulla, whole kidney) are an example of this action and they are also
      widely distributed both in the renal as well as non-renal tissues. Several functional studies
      have shown that activation of A2a R positively affects the glomerular filtration rate and can
      reverse the vasoconstriction of AT II on the descending vasa recta. Both the afferent and
      efferent vasodilatory responses of adenosine can be blocked by specific A2A R antagonists.
      The above information suggests that while adenosine can contribute negatively to IRI with
      vasoconstriction through A1 R, there might be some beneficial action through the activation
      of A2a R.

      The impact of adenosine and its blockade goes actually beyond its effect on the afferent and
      efferent arterioles. It was shown that both infusions of adenosine and the selective A2a R
      agonists protected the kidney after IRI. Rat kidney studies showed that kidney damage was
      significantly reduced when an A2a R agonist (ATL146e) was infused prior to or at the same
      time of IRI. This positive effect had a dose-response curve and was independent of the
      vascular effects of adenosine. Similar protection for IRI was achieved with A2a R agonists
      when the target organ was the bowel, heart, lungs or the spinal cord, suggesting a common
      pathway for ischemia-reperfusion related tissue injury. The immune response has since been
      nominated for being the common mechanism. There is now evidence that bone marrow-derived
      cells are the primary target of A2a R agonists and the damage of IRI requires more than
      vasoactive responses including macrophages, neutrophils, T-lymphocytes and even platelets.
      All these cells harbor A2a R and specific activation of this receptor on the cluster of
      differentiation 4 (CD4) T-lymphocytes may be responsible for protection from IRI. The above
      information suggests that uniformly blocking all adenosine action during IRI may not be the
      best strategy and A1 R blockade along with A2a R stimulation may offer a better outcome.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 7, 2019</start_date>
  <completion_date type="Anticipated">February 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>1 Patient randomization groups
A) Group 1: Aminophylline pre CPB &amp; immediately post cardiopulmonary bypass (CPB)
B) Group 2: No aminophylline prophylaxis</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>There will be 1:1 randomization according to stratification.
That is subjects with circulatory arrest and non-circulatory arrest will be
Separately randomized 1:1 to intervention and placebo.
The randomization will be designed on RedCAP and the entire clinical team will
Be blinded to the treatment.
The initial subject goal will still be 48 patients, 24 intervention (12 circulatory arrest and 12 non-circulatory arrest)
and 24 placebo.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Concentration of Delta urinary neutrophil gelatinase-associated lipocalin (NGAL)</measure>
    <time_frame>at 2 hours post CPB.</time_frame>
    <description>1 Delta urinary NGAL at 6 hours post cardiopulmonary (CPB) and Delta plasma NGAL at 2 hours post CPB.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Concentration of Delta serum cystatin C</measure>
    <time_frame>12 hours post CPB</time_frame>
    <description>Delta serum cystatin C</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Concentration of Delta serum cystatin C</measure>
    <time_frame>24 hours post CPB</time_frame>
    <description>Delta serum cystatin C</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Acute kidney injury stage</measure>
    <time_frame>max point within post CPB 72 hours</time_frame>
    <description>Acute kidney injury stage Pediatric modified Acute Kidney Injury Network criteria (pAKIN) AKI Stage I-&lt;0.5mL (milliliter)/kg/hour for 8 hours AKI Stage II-&lt;0.5mL/kg/hour for 16 hours AKI Stage III-&lt;0.3mL/kg/hour for 24 hours OR Anuria for 16 hours
Using serum creatinine and AKIN criteria</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Urine output during post op</measure>
    <time_frame>first 12 hours and then daily till post op 3 days</time_frame>
    <description>Urine output during post op</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to extubation (hours)</measure>
    <time_frame>during hospitalization, up to 8 days</time_frame>
    <description>Time to extubation (hours) number of hours post surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to chest closure (hours)</measure>
    <time_frame>during hospitalizaiton, up to 3 days</time_frame>
    <description>Time to chest closure (hours) from start time of incision to chest closure during procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to discharge from cardiovascular intensive care unit (CVICU) (days)</measure>
    <time_frame>during hospitalization, approximate 5 days</time_frame>
    <description>Time to discharge from CVICU (days)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of hospital stay (Days).</measure>
    <time_frame>during hospitalization, approximate 8 days</time_frame>
    <description>Duration of hospital stay (Days).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dialysis requirement (yes/no)</measure>
    <time_frame>during hospitalization, approximate 5 days</time_frame>
    <description>Dialysis requirement (yes/no)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to return to preoperative weight.</measure>
    <time_frame>during hospitalization, approximate 8 days</time_frame>
    <description>Time to return to preoperative weight.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inotropic score</measure>
    <time_frame>at 5 days post operative</time_frame>
    <description>Inotropic score Calculation of Inotropic score (IS) and Vasoactive inotropic score (VIS). IS(a) = dopamine dose (lg/kg/min) ? dobutamine dose (lg/kg/min) ? 100 9 epinephrine dose (lg/kg/min) VIS(b) = IS ? 10 9 milrinone dose (lg/kg/ min) ? 10,000 9 vasopressin dose (U/kg/ min) ? 100 9 norepinephrine dose (lg/kg/min) IS inotrope score, VIS vasoactive-inotropic score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inotropic score</measure>
    <time_frame>at 7 days post operative</time_frame>
    <description>Inotropic score Calculation of Inotropic score (IS) and Vasoactive inotropic score (VIS). IS(a) = dopamine dose (lg/kg/min) ? dobutamine dose (lg/kg/min) ? 100 9 epinephrine dose (lg/kg/min) VIS(b) = IS ? 10 9 milrinone dose (lg/kg/ min) ? 10,000 9 vasopressin dose (U/kg/ min) ? 100 9 norepinephrine dose (lg/kg/min) IS inotrope score, VIS vasoactive-inotropic score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peritoneal dialysis catheter output.</measure>
    <time_frame>during hospitalization, up to 8 days</time_frame>
    <description>Peritoneal dialysis catheter output through study completion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transfusion requirements intraoperatively and postoperatively</measure>
    <time_frame>during hospitalization, up to 8 days</time_frame>
    <description>Transfusion requirements intraoperatively and postoperatively through study completion</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Acute Kidney Injury</condition>
  <arm_group>
    <arm_group_label>Aminophylline pre CPB &amp; immediately post CPB</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aminophylline</intervention_name>
    <description>Aminophylline pre cardiopulmonary bypass and immediately post cardiopulmonary bypass. The dose will be Aminophylline 5 mg/kg/dose, max 350 mg slow infusion. The infusion rate duration will be standardized to 20 minutes. There will be no other aminophylline treatments for the first post-op five days.</description>
    <arm_group_label>Aminophylline pre CPB &amp; immediately post CPB</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>The placebo group will not receive any aminophylline treatments for the first post-op five days</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Cohort 1

        ° All children undergoing open heart surgery for congenital heart defects with or

        without circulatory arrest

          -  Neonates (&lt;28 days old) and infants (&lt;1 years of age)

          -  Hypoplastic L heart syndrome or its variants.

          -  Coarctation with aortic arch hypoplasia.

          -  Interrupted aortic arch.

          -  TAPVR (Total anomalous pulmonary venous return)

          -  Patients with complex congenital heart defects

        Cohort 2:

          -  Orthotopic heart transplantation patients.

          -  Congenital heart defects

          -  Cardiomyopathy (Dilated/ hypertrophic)

        Exclusion Criteria:

          -  Children under the age of 12 months undergoing bypass for any condition that is not
             categorized as congenital heart defect

          -  History of seizures

          -  History of significant tachyarrhythmia.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>1 Year</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ali M Onder, MD</last_name>
    <phone>304-282-8550</phone>
    <email>aonder@uthsc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kerry Moore, RN</last_name>
    <phone>901-287-6871</phone>
    <email>kerry.moore@lebonheur.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>LeBonheur Children's Hospital</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ali M Onder, MD</last_name>
      <phone>901-287-5437</phone>
      <email>aonder@uthsc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Kerry Moore, RN</last_name>
      <phone>901-287-6871</phone>
      <email>kerry.moore@lebonheur.org</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>1.KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kidney Int. Suppl 2 ; 2012:1-138</citation>
  </reference>
  <reference>
    <citation>Bojan M, Gioanni S, Vouhé PR, Journois D, Pouard P. Early initiation of peritoneal dialysis in neonates and infants with acute kidney injury following cardiac surgery is associated with a significant decrease in mortality. Kidney Int. 2012 Aug;82(4):474-81.</citation>
    <PMID>22622499</PMID>
  </reference>
  <reference>
    <citation>11.Gouyon JB, Guignard JP. Glomerular filtration rates in neonates. In Oh w, Guignard JP, Baumgart S (Eds.): Nephrology and Fluid / Electrolyte Physiology, First edn (pp 79-96). Philadelphia: Saunders Elsevier 2008</citation>
  </reference>
  <reference>
    <citation>Linden J and Jacobson KA. Molecular biology and pharmacology of adenosine receptors. Cardiovascular Biology of Purines, 1-20 (Eds Burnstock G et al.) Dordrecht: Kluwer Academic Publishers.</citation>
  </reference>
  <results_reference>
    <citation>Rigden SP, Barratt TM, Dillon MJ, De Leval M, Stark J. Acute renal failure complicating cardiopulmonary bypass surgery. Arch Dis Child. 1982 Jun;57(6):425-30.</citation>
    <PMID>7092306</PMID>
  </results_reference>
  <results_reference>
    <citation>Sorof JM, Stromberg D, Brewer ED, Feltes TF, Fraser CD Jr. Early initiation of peritoneal dialysis after surgical repair of congenital heart disease. Pediatr Nephrol. 1999 Oct;13(8):641-5.</citation>
    <PMID>10502118</PMID>
  </results_reference>
  <results_reference>
    <citation>Chan KL, Ip P, Chiu CS, Cheung YF. Peritoneal dialysis after surgery for congenital heart disease in infants and young children. Ann Thorac Surg. 2003 Nov;76(5):1443-9.</citation>
    <PMID>14602265</PMID>
  </results_reference>
  <results_reference>
    <citation>Boigner H, Brannath W, Hermon M, Stoll E, Burda G, Trittenwein G, Golej J. Predictors of mortality at initiation of peritoneal dialysis in children after cardiac surgery. Ann Thorac Surg. 2004 Jan;77(1):61-5.</citation>
    <PMID>14726035</PMID>
  </results_reference>
  <results_reference>
    <citation>Pedersen KR, Povlsen JV, Christensen S, Pedersen J, Hjortholm K, Larsen SH, Hjortdal VE. Risk factors for acute renal failure requiring dialysis after surgery for congenital heart disease in children. Acta Anaesthesiol Scand. 2007 Nov;51(10):1344-9.</citation>
    <PMID>17944638</PMID>
  </results_reference>
  <results_reference>
    <citation>Pedersen KR, Hjortdal VE, Christensen S, Pedersen J, Hjortholm K, Larsen SH, Povlsen JV. Clinical outcome in children with acute renal failure treated with peritoneal dialysis after surgery for congenital heart disease. Kidney Int Suppl. 2008 Apr;(108):S81-6. doi: 10.1038/sj.ki.5002607.</citation>
    <PMID>18379554</PMID>
  </results_reference>
  <results_reference>
    <citation>Ronco C, Haapio M, House AA, Anavekar N, Bellomo R. Cardiorenal syndrome. J Am Coll Cardiol. 2008 Nov 4;52(19):1527-39. doi: 10.1016/j.jacc.2008.07.051. Review.</citation>
    <PMID>19007588</PMID>
  </results_reference>
  <results_reference>
    <citation>Blinder JJ, Goldstein SL, Lee VV, Baycroft A, Fraser CD, Nelson D, Jefferies JL. Congenital heart surgery in infants: effects of acute kidney injury on outcomes. J Thorac Cardiovasc Surg. 2012 Feb;143(2):368-74. doi: 10.1016/j.jtcvs.2011.06.021. Epub 2011 Jul 27.</citation>
    <PMID>21798562</PMID>
  </results_reference>
  <results_reference>
    <citation>Gouyon JB, Guignard JP. Functional renal insufficiency: role of adenosine. Biol Neonate. 1988;53(4):237-42. Review.</citation>
    <PMID>3046670</PMID>
  </results_reference>
  <results_reference>
    <citation>Hall JE, Granger JP, Hester RL. Interactions between adenosine and angiotensin II in controlling glomerular filtration. Am J Physiol. 1985 Mar;248(3 Pt 2):F340-6.</citation>
    <PMID>3883810</PMID>
  </results_reference>
  <results_reference>
    <citation>Hansen PB, Schnermann J. Vasoconstrictor and vasodilator effects of adenosine in the kidney. Am J Physiol Renal Physiol. 2003 Oct;285(4):F590-9. Review.</citation>
    <PMID>12954591</PMID>
  </results_reference>
  <results_reference>
    <citation>Rabb H. The promise of immune cell therapy for acute kidney injury. J Clin Invest. 2012 Nov;122(11):3852-4. doi: 10.1172/JCI66455. Epub 2012 Oct 24.</citation>
    <PMID>23093787</PMID>
  </results_reference>
  <results_reference>
    <citation>Fredholm BB, IJzerman AP, Jacobson KA, Klotz KN, Linden J. International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol Rev. 2001 Dec;53(4):527-52. Review.</citation>
    <PMID>11734617</PMID>
  </results_reference>
  <results_reference>
    <citation>Pawelczyk T, Grden M, Rzepko R, Sakowicz M, Szutowicz A. Region-specific alterations of adenosine receptors expression level in kidney of diabetic rat. Am J Pathol. 2005 Aug;167(2):315-25.</citation>
    <PMID>16049319</PMID>
  </results_reference>
  <results_reference>
    <citation>Navar LG, Inscho EW, Majid SA, Imig JD, Harrison-Bernard LM, Mitchell KD. Paracrine regulation of the renal microcirculation. Physiol Rev. 1996 Apr;76(2):425-536. Review.</citation>
    <PMID>8618962</PMID>
  </results_reference>
  <results_reference>
    <citation>Vitzthum H, Weiss B, Bachleitner W, Krämer BK, Kurtz A. Gene expression of adenosine receptors along the nephron. Kidney Int. 2004 Apr;65(4):1180-90.</citation>
    <PMID>15086457</PMID>
  </results_reference>
  <results_reference>
    <citation>Silldorff EP, Pallone TL. Adenosine signaling in outer medullary descending vasa recta. Am J Physiol Regul Integr Comp Physiol. 2001 Mar;280(3):R854-61.</citation>
    <PMID>11171666</PMID>
  </results_reference>
  <results_reference>
    <citation>Nishiyama A, Inscho EW, Navar LG. Interactions of adenosine A1 and A2a receptors on renal microvascular reactivity. Am J Physiol Renal Physiol. 2001 Mar;280(3):F406-14.</citation>
    <PMID>11181402</PMID>
  </results_reference>
  <results_reference>
    <citation>Okusa MD, Linden J, Macdonald T, Huang L. Selective A2A adenosine receptor activation reduces ischemia-reperfusion injury in rat kidney. Am J Physiol. 1999 Sep;277(3):F404-12. doi: 10.1152/ajprenal.1999.277.3.F404.</citation>
    <PMID>10484524</PMID>
  </results_reference>
  <results_reference>
    <citation>Lee HT, Emala CW. Systemic adenosine given after ischemia protects renal function via A(2a) adenosine receptor activation. Am J Kidney Dis. 2001 Sep;38(3):610-8.</citation>
    <PMID>11532695</PMID>
  </results_reference>
  <results_reference>
    <citation>Okusa MD, Linden J, Huang L, Rosin DL, Smith DF, Sullivan G. Enhanced protection from renal ischemia-reperfusion [correction of ischemia:reperfusion] injury with A(2A)-adenosine receptor activation and PDE 4 inhibition. Kidney Int. 2001 Jun;59(6):2114-25. Erratum in: Kidney Int 2001 Aug;60(2):820.</citation>
    <PMID>11380813</PMID>
  </results_reference>
  <results_reference>
    <citation>Reece TB, Davis JD, Okonkwo DO, Maxey TS, Ellman PI, Li X, Linden J, Tribble CG, Kron IL, Kern JA. Adenosine A2A analogue reduces long-term neurologic injury after blunt spinal trauma. J Surg Res. 2004 Sep;121(1):130-4.</citation>
    <PMID>15313386</PMID>
  </results_reference>
  <results_reference>
    <citation>Ross SD, Tribble CG, Linden J, Gangemi JJ, Lanpher BC, Wang AY, Kron IL. Selective adenosine-A2A activation reduces lung reperfusion injury following transplantation. J Heart Lung Transplant. 1999 Oct;18(10):994-1002.</citation>
    <PMID>10561110</PMID>
  </results_reference>
  <results_reference>
    <citation>Odashima M, Bamias G, Rivera-Nieves J, Linden J, Nast CC, Moskaluk CA, Marini M, Sugawara K, Kozaiwa K, Otaka M, Watanabe S, Cominelli F. Activation of A2A adenosine receptor attenuates intestinal inflammation in animal models of inflammatory bowel disease. Gastroenterology. 2005 Jul;129(1):26-33.</citation>
    <PMID>16012931</PMID>
  </results_reference>
  <results_reference>
    <citation>Glover DK, Riou LM, Ruiz M, Sullivan GW, Linden J, Rieger JM, Macdonald TL, Watson DD, Beller GA. Reduction of infarct size and postischemic inflammation from ATL-146e, a highly selective adenosine A2A receptor agonist, in reperfused canine myocardium. Am J Physiol Heart Circ Physiol. 2005 Apr;288(4):H1851-8. Epub 2004 Dec 9.</citation>
    <PMID>15591104</PMID>
  </results_reference>
  <results_reference>
    <citation>Day YJ, Huang L, Ye H, Li L, Linden J, Okusa MD. Renal ischemia-reperfusion injury and adenosine 2A receptor-mediated tissue protection: the role of CD4+ T cells and IFN-gamma. J Immunol. 2006 Mar 1;176(5):3108-14.</citation>
    <PMID>16493070</PMID>
  </results_reference>
  <results_reference>
    <citation>Vallon V, Mühlbauer B, Osswald H. Adenosine and kidney function. Physiol Rev. 2006 Jul;86(3):901-40. Review.</citation>
    <PMID>16816141</PMID>
  </results_reference>
  <results_reference>
    <citation>Gouyon JB, Guignard JP. Theophylline prevents the hypoxemia-induced renal hemodynamic changes in rabbits. Kidney Int. 1988 Jun;33(6):1078-83.</citation>
    <PMID>3404810</PMID>
  </results_reference>
  <results_reference>
    <citation>Bakr AF. Prophylactic theophylline to prevent renal dysfunction in newborns exposed to perinatal asphyxia--a study in a developing country. Pediatr Nephrol. 2005 Sep;20(9):1249-52. Epub 2005 Jun 10.</citation>
    <PMID>15947981</PMID>
  </results_reference>
  <results_reference>
    <citation>Ng GY, Baker EH, Farrer KF. Aminophylline as an adjunct diuretic for neonates--a case series. Pediatr Nephrol. 2005 Feb;20(2):220-2. Epub 2004 Dec 4.</citation>
    <PMID>15583947</PMID>
  </results_reference>
  <results_reference>
    <citation>Jenik AG, Ceriani Cernadas JM, Gorenstein A, Ramirez JA, Vain N, Armadans M, Ferraris JR. A randomized, double-blind, placebo-controlled trial of the effects of prophylactic theophylline on renal function in term neonates with perinatal asphyxia. Pediatrics. 2000 Apr;105(4):E45.</citation>
    <PMID>10742366</PMID>
  </results_reference>
  <results_reference>
    <citation>Bhat MA, Shah ZA, Makhdoomi MS, Mufti MH. Theophylline for renal function in term neonates with perinatal asphyxia: a randomized, placebo-controlled trial. J Pediatr. 2006 Aug;149(2):180-4.</citation>
    <PMID>16887430</PMID>
  </results_reference>
  <results_reference>
    <citation>McLaughlin GE, Abitbol CL. Reversal of oliguric tacrolimus nephrotoxicity in children. Nephrol Dial Transplant. 2005 Jul;20(7):1471-5. Epub 2005 Apr 19.</citation>
    <PMID>15840666</PMID>
  </results_reference>
  <results_reference>
    <citation>Krämer BK, Preuner J, Ebenburger A, Kaiser M, Bergner U, Eilles C, Kammerl MC, Riegger GA, Birnbaum DE. Lack of renoprotective effect of theophylline during aortocoronary bypass surgery. Nephrol Dial Transplant. 2002 May;17(5):910-5.</citation>
    <PMID>11981083</PMID>
  </results_reference>
  <results_reference>
    <citation>Mahaldar AR, Sampathkumar K, Raghuram AR, Kumar S, Ramakrishnan M, Mahaldar DA. Risk prediction of acute kidney injury in cardiac surgery and prevention using aminophylline. Indian J Nephrol. 2012 May;22(3):179-83. doi: 10.4103/0971-4065.98752.</citation>
    <PMID>23087551</PMID>
  </results_reference>
  <results_reference>
    <citation>Aki Y, Tomohiro A, Nishiyama A, Kiyomoto K, Kimura S, Abe Y. Effects of KW-3902, a selective and potent adenosine A1 receptor antagonist, on renal hemodynamics and urine formation in anesthetized dogs. Pharmacology. 1997 Oct;55(4):193-201.</citation>
    <PMID>9396079</PMID>
  </results_reference>
  <results_reference>
    <citation>Yao K, Ina Y, Nagashima K, Ohno T, Karasawa A. Effect of the selective adenosine A1-receptor antagonist KW-3902 on lipopolysaccharide-induced reductions in urine volume and renal blood flow in anesthetized dogs. Jpn J Pharmacol. 2000 Nov;84(3):310-5.</citation>
    <PMID>11138732</PMID>
  </results_reference>
  <results_reference>
    <citation>Givertz MM, Massie BM, Fields TK, Pearson LL, Dittrich HC; CKI-201 and CKI-202 Investigators. The effects of KW-3902, an adenosine A1-receptor antagonist,on diuresis and renal function in patients with acute decompensated heart failure and renal impairment or diuretic resistance. J Am Coll Cardiol. 2007 Oct 16;50(16):1551-60. Epub 2007 Oct 1.</citation>
    <PMID>17936154</PMID>
  </results_reference>
  <results_reference>
    <citation>Cotter G, Dittrich HC, Weatherley BD, Bloomfield DM, O'Connor CM, Metra M, Massie BM; Protect Steering Committee, Investigators, and Coordinators. The PROTECT pilot study: a randomized, placebo-controlled, dose-finding study of the adenosine A1 receptor antagonist rolofylline in patients with acute heart failure and renal impairment. J Card Fail. 2008 Oct;14(8):631-40. doi: 10.1016/j.cardfail.2008.08.010. Epub 2008 Sep 14.</citation>
    <PMID>18926433</PMID>
  </results_reference>
  <results_reference>
    <citation>Massie BM, O'Connor CM, Metra M, Ponikowski P, Teerlink JR, Cotter G, Weatherley BD, Cleland JG, Givertz MM, Voors A, DeLucca P, Mansoor GA, Salerno CM, Bloomfield DM, Dittrich HC; PROTECT Investigators and Committees. Rolofylline, an adenosine A1-receptor antagonist, in acute heart failure. N Engl J Med. 2010 Oct 7;363(15):1419-28. doi: 10.1056/NEJMoa0912613.</citation>
    <PMID>20925544</PMID>
  </results_reference>
  <results_reference>
    <citation>Voors AA, Dittrich HC, Massie BM, DeLucca P, Mansoor GA, Metra M, Cotter G, Weatherley BD, Ponikowski P, Teerlink JR, Cleland JG, O'Connor CM, Givertz MM. Effects of the adenosine A1 receptor antagonist rolofylline on renal function in patients with acute heart failure and renal dysfunction: results from PROTECT (Placebo-Controlled Randomized Study of the Selective Adenosine A1 Receptor Antagonist Rolofylline for Patients Hospitalized with Acute Decompensated Heart Failure and Volume Overload to Assess Treatment Effect on Congestion and Renal Function). J Am Coll Cardiol. 2011 May 10;57(19):1899-907. doi: 10.1016/j.jacc.2010.11.057.</citation>
    <PMID>21545947</PMID>
  </results_reference>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>February 20, 2019</study_first_submitted>
  <study_first_submitted_qc>March 28, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 1, 2019</study_first_posted>
  <last_update_submitted>March 28, 2019</last_update_submitted>
  <last_update_submitted_qc>March 28, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 1, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Le Bonheur Children's Hospital</investigator_affiliation>
    <investigator_full_name>Ali Mirza Onder, MD</investigator_full_name>
    <investigator_title>Associate Professor UTHSC</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Kidney Injury</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aminophylline</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

